Penserra Capital Management LLC Acquires Shares of 22,271 Option Care Health, Inc. (NASDAQ:OPCH)

Penserra Capital Management LLC purchased a new stake in shares of Option Care Health, Inc. (NASDAQ:OPCH - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 22,271 shares of the company's stock, valued at approximately $778,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Murphy & Mullick Capital Management Corp purchased a new stake in Option Care Health in the fourth quarter worth about $26,000. Signaturefd LLC lifted its position in Option Care Health by 487.9% during the fourth quarter. Signaturefd LLC now owns 1,211 shares of the company's stock valued at $28,000 after purchasing an additional 1,005 shares during the period. Quadrant Capital Group LLC lifted its position in Option Care Health by 172.8% during the fourth quarter. Quadrant Capital Group LLC now owns 1,735 shares of the company's stock valued at $40,000 after purchasing an additional 1,099 shares during the period. Public Employees Retirement System of Ohio lifted its position in Option Care Health by 21.6% during the fourth quarter. Public Employees Retirement System of Ohio now owns 1,870 shares of the company's stock valued at $43,000 after purchasing an additional 332 shares during the period. Finally, Johnson Financial Group Inc. bought a new position in Option Care Health in the fourth quarter worth approximately $47,000. Hedge funds and other institutional investors own 98.05% of the company's stock.

Analyst Ratings Changes

Several research firms have weighed in on OPCH. Barrington Research reiterated an "outperform" rating and issued a $38.00 price target on shares of Option Care Health in a research report on Thursday. UBS Group raised shares of Option Care Health from a "neutral" rating to a "buy" rating and increased their price objective for the stock from $38.00 to $40.00 in a research note on Wednesday, April 30th. Finally, JMP Securities reissued a "market outperform" rating and issued a $36.00 price objective on shares of Option Care Health in a research note on Wednesday, June 18th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $35.50.

Option Care Health Price Performance

OPCH traded down $0.61 during trading on Friday, hitting $29.88. 1,042,047 shares of the company traded hands, compared to its average volume of 1,852,837. The company has a market cap of $4.89 billion, a PE ratio of 24.10, a P/E/G ratio of 1.81 and a beta of 0.73. The stock's 50-day simple moving average is $31.80 and its two-hundred day simple moving average is $31.42. Option Care Health, Inc. has a 1 year low of $21.39 and a 1 year high of $35.53. The company has a current ratio of 1.54, a quick ratio of 1.02 and a debt-to-equity ratio of 0.82.

Option Care Health (NASDAQ:OPCH - Get Free Report) last posted its earnings results on Tuesday, April 29th. The company reported $0.40 earnings per share for the quarter, beating the consensus estimate of $0.36 by $0.04. The company had revenue of $1.33 billion during the quarter, compared to analysts' expectations of $1.26 billion. Option Care Health had a net margin of 4.12% and a return on equity of 16.90%. Option Care Health's quarterly revenue was up 16.3% on a year-over-year basis. During the same period last year, the company posted $0.26 earnings per share. As a group, sell-side analysts anticipate that Option Care Health, Inc. will post 1.22 earnings per share for the current fiscal year.

Option Care Health Company Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.